ClinicalTrials.gg
RecruitingNCT05304962Updated Aug 12, 2026

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

A Phase 1 interventional study of RGT-419B and RGT-419B in combination with hormonal therapy in Breast Cancer, sponsored by Regor Pharmaceuticals Inc.. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Regor Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 64 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female >/= 18 years old
  2. Performance Status 0 to 1
  3. Subjects must have or cytologically confirmed diagnosis of ER+, - ABC consistent with ASCO CAP guidelines that is locally advanced and unresectable (Stage III) or (Stage IV) BC.
  4. Measurable AND evaluable lesions at baseline per v1.1.
  5. Eligible subjects must meet all of the following criteria:

    • Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4/6i is permitted in the post-surgical setting);

      • Subjects must have received therapy for ≥3 months in the MBC setting, or for ≥6 months in the adjuvant setting, prior to progression
    • Progression after ≤3 lines of prior HT therapy (regardless of whether it is HT alone or in combination with other therapies)

      • Prior HT combination agents, including SERD, SERM or AI, must have received formal approval by regulatory agency.
    • ≤ 1 in the metastatic setting
  6. Adequate organ function
  7. Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  1. Presence of visceral with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease
  2. Pregnant or planning to become pregnant
  3. Prior irradiation to >25% of the bone marrow and/or inadequate bone marrow function or evidence of end-organ damage
  4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14-28 days prior to Cycle 1, Day 1
  5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol
  6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Arm A

    RGT-419B given alone as monotherapy

    Drug: RGT-419B

  • Experimental
    Arm B

    RGT-419B in combination with Hormonal Therapy

    Drug: RGT-419B in combination with hormonal therapy

Interventions

  • oral capsules

  • DrugRGT-419B in combination with hormonal therapy

    Drug page: Vustanaciclib

    RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)

06

What researchers measure

Primary outcomes

  1. Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy

    Number of subjects who have a confirmed DLT at each cohort dose level in singlet and doublet study arms during the first 28-day cycle of RGT-419B treatment.

    Time frame: 4 weeks (1 cycle)

Secondary outcomes

  1. Safety & Tolerability - Incidence, Severity, and Causality of all Treatment Emergent Adverse Events (TEAEs)

    Incidence, severity, and causality of all TEAEs will be assessed for all patient participating from Day 1 dosing through end of study.

    Time frame: through study completion, an average of 1 year

  2. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cmax

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  3. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve (AUC0-t)

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  4. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve to Infinity (AUC0-inf)

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  5. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Plasma Decay Half-Life (t 1/2)

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  6. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  7. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Accumulation rate after multiple doses

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  8. Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cumulative urinary excretion

    Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification

    Time frame: through study completion, an average of 1 year

  9. Tumor Response assessed by Investigator according to RECIST v1.1

    Tumor response measured by radiologic imaging techniques at baseline and throughout the study

    Time frame: through study completion, an average of 1 year

  10. QTc Interval - Changes in corrected QT interval

    Number of subjects with a clinically significant increase from baseline in corrected QT (QTc) interval on repeated ECGs during RGT-419B monotherapy.

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. Symptom Burden

    Change from baseline in symptom burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) from baseline to end of treatment

    Time frame: through study completion, an average of 1 year

07

Study locations

7 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 57 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 31, 2022
StartActual
Mar 4, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 31, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05304962
Lead sponsor
Regor Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Mar 4, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Joanna Dojillo, MSc
Contact
joanna.dojillo@regor.com
617-315-9070
Regor Pharmaceuticals Central Office
Contact
rgt-419b_01-101@regor.com
617-315-9070

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vustanaciclib

Start the discussion